Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics Inc (NY: LCTX )

1.190 -0.080 (-6.30%)
Official Closing Price Updated: 8:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 579,786
Open 1.270
Bid (Size) 1.200 (1)
Ask (Size) 1.290 (5)
Prev. Close 1.270
Today's Range 1.185 - 1.270
52wk Range 1.020 - 1.580
Shares Outstanding 174,986,671
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics
Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and... 
Via Benzinga

Performance

YTD
-3.25%
-3.25%
1 Month
-12.50%
-12.50%
3 Month
-19.59%
-19.59%
6 Month
-15.00%
-15.00%
1 Year
N/A
N/A

More News

Read More
Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Earnings Preview
Via Benzinga
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Lineage Cell Therapeutics: Q1 Earnings Insights
Via Benzinga
Lineage Cell Therapeutics's Return On Capital Employed Overview
Via Benzinga
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 10, 2023
Via Benzinga
Lineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune Response
Via Benzinga
Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Harley-Davidson, Sportsman's Warehouse And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Lineage to Present at 2023 AAPS National Biotechnology Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
3 Penny Stocks to Buy During Market Downturns
Via InvestorPlace
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.